Stock JNJCL JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

News Johnson & Johnson Santiago S.E.

Equities

JNJCL

US4781601046

End-of-day quote Santiago S.E.
Other stock markets
 03:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
1,55,930 CLP 0.00% Intraday chart for Johnson & Johnson 0.00% +14.33%
03:23pm Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma MT
08:00am Dealmakers optimistic on global M&A prospects despite sluggish growth RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
PU
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma
MT
Dealmakers optimistic on global M&A prospects despite sluggish growth
RE
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)
AQ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug
RE
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program
AQ
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit
RE
J&J: 50M pupils helped through 'Sight for Kids' program
CF
Johnson & Johnson completes acquisition of Proteologix, Inc.
AQ
Sector Update: Health Care Stocks Edge Up in Afternoon Trading
MT
Johnson & Johnson: filing in Crohn's disease
CF
Johnson & Johnson: acquisition of Proteologix completed
CF
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix
MT
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications
AQ
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJCL Stock
  5. News Johnson & Johnson